Heat Biologics, Inc. (HTBX): Price and Financial Metrics
HTBX Stock Summary
- HTBX's price/sales ratio is 57.32; that's higher than the P/S ratio of 94.95% of US stocks.
- In terms of volatility of its share price, HTBX is more volatile than 97.55% of stocks we're observing.
- Heat Biologics Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -71.8%, greater than the shareholder yield of only 3.47% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Heat Biologics Inc are SITM, PI, GWRE, UTHR, and CLGN.
- Visit HTBX's SEC page to see the company's official filings. To visit the company's web site, go to www.heatbio.com.
HTBX Stock Price Chart Interactive Chart >
HTBX Price/Volume Stats
| Current price | $6.71 | 52-week high | $30.10 |
| Prev. close | $6.65 | 52-week low | $3.50 |
| Day low | $6.56 | Volume | 258,700 |
| Day high | $6.91 | Avg. volume | 2,099,281 |
| 50-day MA | $8.12 | Dividend yield | N/A |
| 200-day MA | $8.77 | Market Cap | 170.50M |
Heat Biologics, Inc. (HTBX) Company Bio
Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.
Latest HTBX News From Around the Web
Below are the latest news stories about Heat Biologics Inc that investors may wish to consider to help them evaluate HTBX as an investment opportunity.
Heat Biologics Announces New Preclinical Data on PTX-35, Demonstrating Decreased Regulatory T-cell (Treg) Activity and Delayed Tumor Progression at American Association for Cancer Research (AACR) Annual Meeting 2021DURHAM, NC / ACCESSWIRE / April 12, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today reported that promising new preclinical data of PTX-35 is presented at the AACR Annual Meeting 2021. |
Heat Biologics Provides Year-End Business UpdateDURHAM, NC / ACCESSWIRE / March 25, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today provided financial, clinical and operational updates for the year ended December 31, 2020. |
Heat Biologics Earnings Report: Here’s what to expect from Stock market Insights & financial analysisHeat Biologics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by… |
Heat Biologics Wall street estimates Earnings report Stock market Insights & financial analysisHeat Biologics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by… |
Covid-19 Product Market With Top Key Players like 3M, Cardinal Health, Kimberly- Clark, Johnson and Johnson, Sanofi, Ansell, Abbott Laboratories, BD, Henry Schein, Heat BiologicsAn off-the-shelf report on Covid-19 Product Market which has been compiled after an in-depth analysis of the market trends prevailing across five geographies (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). Various segments of the market such as |
HTBX Price Returns
| 1-mo | -11.71% |
| 3-mo | -2.61% |
| 6-mo | -19.45% |
| 1-year | 66.51% |
| 3-year | -14.41% |
| 5-year | -85.90% |
| YTD | 25.19% |
| 2020 | 61.20% |
| 2019 | -51.53% |
| 2018 | -74.41% |
| 2017 | -55.47% |
| 2016 | -64.75% |
Continue Researching HTBX
Here are a few links from around the web to help you further your research on Heat Biologics Inc's stock as an investment opportunity:Heat Biologics Inc (HTBX) Stock Price | Nasdaq
Heat Biologics Inc (HTBX) Stock Quote, History and News - Yahoo Finance
Heat Biologics Inc (HTBX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...